

Filed: March 27, 2017

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.

Petitioner

v.

JANSSEN ONCOLOGY, INC.

Patent Owner

---

Case No. IPR2016-01332  
U.S. Patent No. 8,822,438

---

**MOTION FOR *PRO HAC VICE* ADMISSION  
OF SHANNON M. BLOODWORTH**

## **I. Statement of Precise Relief Requested**

Mylan Pharmaceuticals Inc. (“Mylan”) hereby respectfully requests that the Patent Trial and Appeal Board (the “Board”) admit Shannon M. Bloodworth, *pro hac vice* in this proceeding under 37 C.F.R. § 42.10(c).

Patent Owner has stated it will not oppose this motion.

## **II. Statement of Facts Showing Good Cause for the Board to Recognize Counsel *Pro Hac Vice* During the Proceeding**

Under 37 C.F.R. § 42.10(c), the Board may admit counsel *pro hac vice* for good cause, so long as lead counsel is a registered practitioner and subject to any other conditions the Board requires. Under Section 42.10(c), good cause includes when “counsel is an experienced litigating attorney and has an established familiarity with the subject matter at issue in the proceeding.” This motion satisfies the requirements of Section 42.10(c):

1. Lead counsel, Brandon M. White, is a registered practitioner.
2. Ms. Bloodworth is an experienced patent litigator and has an established familiarity with the subject matter at issue here, as shown in her accompanying March 27, 2017 Declaration (“Bloodworth Decl.” (Ex. 1084)), filed currently with this motion. That declaration shows that Ms. Bloodworth has been a litigator for more than 15 years. She is a member in good standing of the District of Columbia, Maryland, Virginia, Wisconsin, and is also admitted in several federal courts. Ms. Bloodworth is also familiar with the subject matter of this case,

including U.S. Patent No. 8,822,438 and its prosecution history, the underlying technology, and the prior art cited by the petitioner in this matter. Bloodworth Decl. ¶¶ 8-9.

3. In her declaration, Ms. Bloodworth also attests to each of the listed items required by the Order – Authorizing Motion for *Pro Hac Vice* Admission – 37 C.F.R. § 42.10 in IPR2013-00639. See Bloodworth Decl. ¶¶ 2-13.

### III. Conclusion

For the foregoing reasons, Mylan respectfully requests that the Board admit Shannon M. Bloodworth, *pro hac vice* in this proceeding.

Dated: March 27, 2017

/Brandon M. White/

Brandon M. White

Reg. No. 52,354

PERKINS COIE LLP

700 13th Street, NW, Suite 600

Washington, D.C. 20005

Telephone: (202) 654-6204

Facsimile: (202) 654-6211

Email: [bmwhite@perkinscoie.com](mailto:bmwhite@perkinscoie.com)

*Attorney for Mylan Pharmaceuticals Inc.*

## CERTIFICATE OF SERVICE

The undersigned hereby certifies that the foregoing:

1. MOTION FOR *PRO HAC VICE* ADMISSION OF SHANNON M. BLOODWORTH, and
2. DECLARATION OF SHANNON M. BLOODWORTH IN SUPPORT OF MOTION FOR *PRO HAC VICE* ADMISSION OF SHANNON M. BLOODWORTH

was served electronically via email as follows:

Patent Owners:

Dianne B. Elderkin  
Barbara L. Mullin  
Ruben H. Munoz  
Akin Gump Strauss Hauer & Feld LLP  
JANS-ZYTIGA@akingump.com

David T. Pritikin  
Bindu Donovan  
Sidley Austin LLP  
ZytigaIPRTeam@sidley.com

Dated: March 27, 2017

/Brandon M. White/

Brandon M. White

*Attorney for Mylan Pharmaceuticals Inc.*